Halozyme Therapeutics | HALO - Passività Correnti





Passività Correnti Cambiamento Data
Acadia Pharmaceuticals USD 305.52M 28.41M 2026-03
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Amarin USD 179.64M 14.82M 2026-03
Amgen USD 24.96B 534M 2026-03
Baxter International USD 3.69B 723M 2026-03
Cara Therapeutics USD 11.04M 2K 2025-12
Cytokinetics USD 199.18M 3.27M 2026-03
DBV Technologies USD 58.02M 8.54M 2025-12
Eli Lilly USD 36.63B 1.41B 2026-03
Esperion Therapeutics USD 300.36M 451K 2026-03
Halozyme Therapeutics USD 363.21M 186.12M 2026-03
Intrexon USD 23.02M 38K 2024-06
Ionis Pharmaceuticals USD 717M 66M 2026-03
MannKind USD 134.56M 36.47M 2026-03
Minerva Neurosciences USD 2.29M 381K 2025-12
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Pfizer USD 34.35B 2.64B 2026-03
Rigel Pharmaceuticals USD 94.4M 7.76M 2025-09
United Therapeutics USD 599.1M 38.5M 2026-03
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12